Zymeworks Inc. announced acceptance of five abstracts for poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place at the San Diego Convention Center in San Diego, CA from April 5-10, 2024. Presentation Details: Antibody-Drug Conjugates: Title: ZW191 - a FRa-targeting antibody drug conjugate with strong preclinical activity across multiple FRa-expressing indications; Abstract: 1862; Session Category: Experimental and Molecular Therapeutics; Session Title: Antibody-Based Technologies and New Inhibitors. Title: Screening novel format antibodies to design bispecific ADCs that address target heterogeneity; Abstract: 2052; Session Category: Experimental and Molecular Therapeutics; Session Title: New Technologies.

Title: Development of three-dimensional cancer cell line spheroid models for the in vitro functional characterization of cytotoxic antibody-drug conjugates; Abstract: 3127; Session Category: Experimental and Molecular Therapeutics; Session Title: Antibody-Drug Conjugates. Multispecific Antibody Therapeutics: Title: DLL3 TriTCE Co-Stim: A next generation trispecific T cell engager with integrated CD28 costimulation for the treatment of DLL3-expressing cancers; Abstract: 6716; Session Category: Immunology; Session Title: Targeted ICEs. Title: TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 costimulation, engineered to improve responses in the treatment of solid tumors; Abstract: 6719; Session Category: Immunology; Session Title: Targeted ICEs.